Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Predicting clinical outcome of therapy-resistant prostate cancer.

Ma X, Huang J.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11090-11092. doi: 10.1073/pnas.1906812116. Epub 2019 May 21. No abstract available.

PMID:
31113882
2.

Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.

Choi SY, Ryu J, You D, Hong JH, Ahn H, Kim CS.

Int J Urol. 2019 Jan;26(1):62-68. doi: 10.1111/iju.13800. Epub 2018 Sep 20.

PMID:
30238513
3.

Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.

Terada N, Akamatsu S, Okada Y, Negoro H, Kobayashi T, Yamasaki T, Matsui Y, Inoue T, Kamba T, Ogawa O.

Int J Clin Oncol. 2016 Dec;21(6):1155-1161. Epub 2016 Jun 28.

PMID:
27351872
4.

The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.

Berg KD, Røder MA, Thomsen FB, Vainer B, Gerds TA, Brasso K, Iversen P.

Prostate. 2015 Oct;75(14):1499-509. doi: 10.1002/pros.23026. Epub 2015 Jun 5.

PMID:
26053696
5.

Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel.

Sümbül AT, Sezer A, Abalı H, Köse F, Gültepe I, Mertsoylu H, Muallaoğlu S, Özyılkan Ö.

Int Urol Nephrol. 2014 Aug;46(8):1531-5. doi: 10.1007/s11255-014-0664-7. Epub 2014 Feb 13.

PMID:
24526335
6.

Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.

Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ.

Int J Urol. 2015 Apr;22(4):362-6. doi: 10.1111/iju.12704. Epub 2015 Feb 24.

7.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR.

Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

8.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
9.

Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer.

D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.

Prostate Cancer Prostatic Dis. 2000 Dec;3(4):259-264.

10.

Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.

de la Taille A, Martínez-Piñeiro L, Cabri P, Houchard A, Schalken J; Triptocare LT Study Group.

BJU Int. 2017 Jan;119(1):74-81. doi: 10.1111/bju.13455. Epub 2016 Mar 23.

11.

Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.

Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ.

Cancer. 2017 Nov 1;123(21):4122-4129. doi: 10.1002/cncr.30844. Epub 2017 Jun 29.

12.
13.

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.

Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM.

Eur Urol. 2017 Nov;72(5):828-834. doi: 10.1016/j.eururo.2017.07.024. Epub 2017 Aug 14.

PMID:
28818355
14.

Castration-resistant prostate cancer: systemic therapy in 2012.

Maluf FC, Smaletz O, Herchenhorn D.

Clinics (Sao Paulo). 2012;67(4):389-94. Review.

15.

A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score.

Yamaguchi Y, Hayashi Y, Ishizuya Y, Takeda K, Nakai Y, Arai Y, Nakayama M, Kakimoto K, Nishimura K.

Jpn J Clin Oncol. 2015 Feb;45(2):197-201. doi: 10.1093/jjco/hyu186. Epub 2014 Nov 7.

PMID:
25381383
16.

[Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].

Ji GJ, Huang C, Song G, Li XS, Song Y, Zhou LQ.

Beijing Da Xue Xue Bao Yi Xue Ban. 2017 Aug 18;49(4):657-662. Chinese.

17.
18.

Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.

Mizokami A, Kadono Y, Kitagawa Y, Izumi K, Konaka H.

Int J Urol. 2017 Aug;24(8):566-572. doi: 10.1111/iju.13372. Epub 2017 Jun 3. Review.

19.

The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.

Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD.

Eur Urol. 2018 Jul;74(1):17-23. doi: 10.1016/j.eururo.2017.08.035. Epub 2017 Sep 20.

PMID:
28939004
20.

Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.

Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zoubeidi A, Collins C, Gleave ME, Lin D, Wang Y.

Eur Urol. 2018 Jun;73(6):949-960. doi: 10.1016/j.eururo.2018.02.019. Epub 2018 Mar 12.

Supplemental Content

Support Center